KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EPS (Weighted Average and Diluted) (2016 - 2026)

Bristol Myers Squibb has reported EPS (Weighted Average and Diluted) over the past 18 years, most recently at $1.31 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 9.17% to $1.31 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.56 through Mar 2026, up 33.33% year-over-year, with the annual reading at $3.46 for FY2025, 178.46% up from the prior year.
  • EPS (Weighted Average and Diluted) was $1.31 for Q1 2026 at Bristol Myers Squibb, up from $0.53 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.31 in Q1 2026 and troughed at -$5.89 in Q1 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.83 (2024), against an average of $0.42.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 650.47% in 2024 and then surged 1225.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.95 in 2022, then decreased by 8.42% to $0.87 in 2023, then tumbled by 95.4% to $0.04 in 2024, then surged by 1225.0% to $0.53 in 2025, then skyrocketed by 147.17% to $1.31 in 2026.
  • Per Business Quant, the three most recent readings for BMY's EPS (Weighted Average and Diluted) are $1.31 (Q1 2026), $0.53 (Q4 2025), and $1.08 (Q3 2025).